The approval from the sponsor Astellas Pharma, Japan, was received for the Site's participation in a randomized, double-blind, placebo-controlled 24-week phase 3b study to study a new medicine for the elimination of moderate and severe vasomotor symptoms (hot flashes) in postmenopausal women for whom hormone replacement therapy is unacceptable.
Another visit of the opening of the center was conducted: we study the drugs of the pharmaceutical company Eli Lilly in a randomized, double-blind, placebo-controlled phase II trial with adaptive design in patients with moderate and severe ulcerative colitis.
An initiation visit took place: patients with Crohn's disease will continue to participate in a new multicenter open extended phase 3 study to assess the long-term efficacy and safety of Mirikizumab in patients with Crohn's disease.
Our Study Site was invited to participate in clinical trials conducted by the Japanese pharmaceutical company Astellas Pharma
